41
TÍTULO: Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
AUTORES: António Almeida; Ana Rita Ferreira; Maria João Costa; Sofia Silva; Khalil Alnajjar; Isabel Bogalho; Francesca Pierdomenico; Susana Esteves; Mafalda Alpoim; Gil Braz; Emilia Cortesão; Ricardo Pinto;
PUBLICAÇÃO: 2017, FONTE: Leukemia Research Reports, VOLUME: 7
INDEXADO EM: CrossRef: 1
NO MEU: ORCID
42
TÍTULO: Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry
AUTORES: Antonio M Almeida; Camille Bedrosian; Alexander Cole; Petra Muus; Hubert Schrezenmeier; Jeff Szer; Wendell F Rosse;
PUBLICAÇÃO: 2017, FONTE: Internal Medicine Journal, VOLUME: 47, NÚMERO: 9
INDEXADO EM: CrossRef: 17
NO MEU: ORCID
43
TÍTULO: Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
AUTORES: Antonio Almeida; Thomas Prebet; Raphael Itzykson; Fernando Ramos; Haifa Al-Ali; Jamile Shammo; Ricardo Pinto; Luca Maurillo; Jaime Wetzel; Pellegrino Musto; Arjan Van De Loosdrecht; Maria Costa; Susana Esteves; Sonja Burgstaller; Reinhard Stauder; Eva Autzinger; Alois Lang; Peter Krippl; Dietmar Geissler; Jose Falantes; Carmen Pedro; Joan Bargay; Guillermo Deben; Ana Garrido; Santiago Bonanad; Maria Diez-Campelo; Sylvain Thepot; Lionel Ades; Wolfgang Sperr; Peter Valent; Pierre Fenaux; Mikkael Sekeres; Richard Greil; Lisa Pleyer; ...Mais
PUBLICAÇÃO: 2017, FONTE: International Journal of Molecular Sciences, VOLUME: 18, NÚMERO: 4
INDEXADO EM: CrossRef: 19
NO MEU: ORCID
44
TÍTULO: Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
AUTORES: Roboz, GJ; Montesinos, P; Selleslag, D; Wei, A; Jang, JH; Falantes, J; Voso, MT; Sayar, H; Porkka, K; Marlton, P; Almeida, A; Mohan, S; Ravandi, F; Garcia Manero, G; Skikne, B; Kantarjian, H;
PUBLICAÇÃO: 2016, FONTE: FUTURE ONCOLOGY, VOLUME: 12, NÚMERO: 3
INDEXADO EM: Scopus WOS CrossRef
NO MEU: ORCID
45
TÍTULO: Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
AUTORES: Valeria Santini; Antonio Almeida; Aristoteles Giagounidis; Stefanie Groepper; Anna Jonasova; Norbert Vey; Ghulam J Mufti; Rena Buckstein; Moshe Mittelman; Uwe Platzbecker; Ofer Shpilberg; Ron Ram; Consuelo del Canizo; Norbert Gattermann; Keiya Ozawa; Alberto Risueno; Kyle J MacBeth; Jianhua H Zhong; Francis Seguy; Albert Hoenekopp; Beach, CL; Pierre Fenaux; ...Mais
PUBLICAÇÃO: 2016, FONTE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 34, NÚMERO: 25
INDEXADO EM: Scopus WOS CrossRef
NO MEU: ORCID
46
TÍTULO: Design and rationale of the QUAZAR lower-risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia
AUTORES: Guillermo Garcia Manero; Antonio Almeida; Aristoteles Giagounidis; Uwe Platzbecker; Regina Garcia; Maria Teresa Voso; Stephen R Larsen; David Valcarcel; Lewis R Silverman; Barry Skikne; Valeria Santini;
PUBLICAÇÃO: 2016, FONTE: BMC Hematology, VOLUME: 16, NÚMERO: 1
INDEXADO EM: Scopus
NO MEU: ORCID
47
TÍTULO: Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients
AUTORES: Álvaro Urbano-Ispizua; Petra Muus; Hubert Schrezenmeier; Antonio M Almeida; Amanda Wilson; Russell E Ware;
PUBLICAÇÃO: 2016, FONTE: Haematologica, VOLUME: 102, NÚMERO: 3
INDEXADO EM: CrossRef: 16
NO MEU: ORCID
48
TÍTULO: Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia
AUTORES: Guillermo Garcia-Manero; Antonio Almeida; Aristoteles Giagounidis; Uwe Platzbecker; Regina Garcia; Maria Teresa Voso; Stephen R Larsen; David Valcarcel; Lewis R Silverman; Barry Skikne; Valeria Santini;
PUBLICAÇÃO: 2016, FONTE: BMC Hematology, VOLUME: 16, NÚMERO: 1
INDEXADO EM: CrossRef: 31
NO MEU: ORCID
49
TÍTULO: Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry
AUTORES: de Swart, L; Smith, A; Johnston, TW; Haase, D; Droste, J; Fenaux, P; Symeonidis, A; Sanz, G; Hellstrom Lindberg, E; Cermak, J; Germing, U; Stauder, R; Georgescu, O; MacKenzie, M; Malcovati, L; Holm, MS; Almeida, AM; Madry, K; Slama, B; Guerci Bresler, A; Sanhes, L; Beyne Rauzy, O; Luno, E; Bowen, D; de Witte, T; ...Mais
PUBLICAÇÃO: 2015, FONTE: BRITISH JOURNAL OF HAEMATOLOGY, VOLUME: 170, NÚMERO: 3
INDEXADO EM: Scopus WOS CrossRef
NO MEU: ORCID
50
TÍTULO: THE EFFECT OF LENALIDOMIDE ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: RESULTS FROM THE MDS-005 TRIAL  Full Text
AUTORES: Santini, V; Almeida, A; Giagounidis, A; Bartiromo, C; Hoenekopp, A; Guo, S; Beach, C; Altincatal, A; Wu, C; Skikne, B; Zhong, J; Hu, H; Fenaux, P;
PUBLICAÇÃO: 2015, FONTE: 20th Congress of European-Hematology-Association in HAEMATOLOGICA, VOLUME: 100
INDEXADO EM: WOS
Página 5 de 9. Total de resultados: 83.